Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 3/20 | 0.48 |
| ▸ | ERN1 | O75460 | 3/20 | 0.48 |
| ▸ | CASR | P41180 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9258765 | 0.93 | ERN1 (0.53) | CTSAERN1CASRDHFRFYN | |
| SCHEMBL9254425 | 0.92 | ERN1 (0.49) | CTSAERN1CASRTSHRDHFR | |
| SCHEMBL16712942 | 0.85 | BACE1 (0.46) | CTSAERN1CASRFYNPIM1 | |
| SCHEMBL18084776 | 0.85 | CASR (0.46) | CTSAERN1CASRDHFRFYN | |
| SCHEMBL16712954 | 0.83 | ERN1 (0.51) | CTSAERN1CASRFYN | |
| SCHEMBL11951612 | 0.83 | CASR (0.53) | CTSAERN1CASRFYNHDAC8 | |
| SCHEMBL16710318 | 0.83 | PDE4B (0.49) | CTSATSHRMAPTHDAC8HDAC4 | |
| SCHEMBL8940819 | 0.82 | HDAC4 (0.50) | ERN1CASRCETPFYNHDAC8 | |
| SCHEMBL2006306 | 0.81 | ADRB2 (0.52) | CTSAERN1CASRAGPAT2 | |
| SCHEMBL5236993 | 0.81 | ADRB2 (0.52) | CTSAERN1CASRAGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | CTSA 2610/4885ERN1 2774/4885CASR 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.